Clinical Trials Browser

Phase 1/2 × LY3295668 erbumine × 1 year × Clear all

NCT05017025 2026-05-20

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Lung Neoplasms